|
Feb 20
|
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
|
|
Jan 2
|
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
|
|
Dec 31
|
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application
|
|
Dec 31
|
Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell
|
|
Dec 30
|
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
|
|
Jul 29
|
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
|
|
Jul 24
|
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
|
|
Jul 23
|
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
|
|
May 24
|
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
|
|
May 24
|
Sector Update: Health Care Stocks Advance Pre-Bell Friday
|
|
May 24
|
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
|
|
May 24
|
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
|
|
May 24
|
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
|
|
May 23
|
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
|
|
May 9
|
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
|
|
May 7
|
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
|
|
Apr 18
|
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
|
|
Apr 4
|
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 18
|
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
|
|
Mar 14
|
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
|